Open Access

ACS Omega

, volume 5 , issue 24 , pages 14750-14758

Epigenetic Reexpression of Hemoglobin F Using Reversible LSD1 Inhibitors: Potential Therapies for Sickle Cell Disease

Steven Holshouser ¹

Rebecca Cafiero ¹

Mayra Robinson ¹

Joy Kirkpatrick ¹

Robert A. Casero ²

Hyacinth I. Hyacinth ³

Patrick M. Woster ¹

Hide authors affiliations Show authors affiliations: 3 affiliations

Department of Drug Discovery and Biomedical Sciences, Medical University of South Carolina, 70 President St., Charleston, South Carolina 29414, United States |

Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, 1650 Orleans St. Room 551, Baltimore, Maryland 21287, United States |

Department of Pediatrics, School of Medicine, Emory University, 2015 Uppergate Dr., Atlanta, Georgia 30322, United States |

Publication type: Journal Article

Publication date: 2020-06-09

American Chemical Society (ACS)

ACS Omega

scimago Q1

wos Q2

SJR: 0.773

CiteScore: 7.1

Impact factor: 4.3

ISSN: 24701343

DOI: 10.1021/acsomega.0c01585

Copy DOI

PubMed ID: 32596612

General Chemistry

General Chemical Engineering

Abstract

Sickle cell disease (SCD) is caused by a single nucleotide polymorphism on chromosome 11 in the β-globin gene. The resulting mutant hemoglobin S (HbS) is a poor oxygen transporter and causes a vari...

Found

1 citation

Larina Lyudmula

56 publications, 361 citations, 2 reviews

h-index: 10

A.E. Favorsky Irkutsk Institute of Chemistry of the Siberian Branch of the Russian Academy of Sciences

Photochemistry Center

Emanuel Institute of Biochemical Physics of the Russian Academy of Sciences

Chungnam National University

Top-30

Journals

	1 2 3
Journal of Medicinal Chemistry	Journal of Medicinal Chemistry, 3, 16.67% Journal of Medicinal Chemistry 3 publications, 16.67%
Frontiers in Pharmacology	Frontiers in Pharmacology, 1, 5.56% Frontiers in Pharmacology 1 publication, 5.56%
Current Organic Chemistry	Current Organic Chemistry, 1, 5.56% Current Organic Chemistry 1 publication, 5.56%
Frontiers in Medicine	Frontiers in Medicine, 1, 5.56% Frontiers in Medicine 1 publication, 5.56%
European Journal of Medicinal Chemistry	European Journal of Medicinal Chemistry, 1, 5.56% European Journal of Medicinal Chemistry 1 publication, 5.56%
Blood Reviews	Blood Reviews, 1, 5.56% Blood Reviews 1 publication, 5.56%
Advanced Genetics	Advanced Genetics, 1, 5.56% Advanced Genetics 1 publication, 5.56%
ChemMedChem	ChemMedChem, 1, 5.56% ChemMedChem 1 publication, 5.56%
Expert Opinion on Drug Discovery	Expert Opinion on Drug Discovery, 1, 5.56% Expert Opinion on Drug Discovery 1 publication, 5.56%
ACS Medicinal Chemistry Letters	ACS Medicinal Chemistry Letters, 1, 5.56% ACS Medicinal Chemistry Letters 1 publication, 5.56%
Chemical and Pharmaceutical Bulletin	Chemical and Pharmaceutical Bulletin, 1, 5.56% Chemical and Pharmaceutical Bulletin 1 publication, 5.56%
Archiv der Pharmazie	Archiv der Pharmazie, 1, 5.56% Archiv der Pharmazie 1 publication, 5.56%
Medicinal Chemistry Research	Medicinal Chemistry Research, 1, 5.56% Medicinal Chemistry Research 1 publication, 5.56%
Russian Chemical Reviews	Russian Chemical Reviews, 1, 5.56% Russian Chemical Reviews 1 publication, 5.56%
Biomolecules	Biomolecules, 1, 5.56% Biomolecules 1 publication, 5.56%
International Journal of Molecular Sciences	International Journal of Molecular Sciences, 1, 5.56% International Journal of Molecular Sciences 1 publication, 5.56%
	1 2 3

Publishers

	1 2 3 4
American Chemical Society (ACS)	American Chemical Society (ACS), 4, 22.22% American Chemical Society (ACS) 4 publications, 22.22%
Wiley	Wiley, 3, 16.67% Wiley 3 publications, 16.67%
Frontiers Media S.A.	Frontiers Media S.A., 2, 11.11% Frontiers Media S.A. 2 publications, 11.11%
Elsevier	Elsevier, 2, 11.11% Elsevier 2 publications, 11.11%
MDPI	MDPI, 2, 11.11% MDPI 2 publications, 11.11%
Bentham Science Publishers Ltd.	Bentham Science Publishers Ltd., 1, 5.56% Bentham Science Publishers Ltd. 1 publication, 5.56%
Taylor & Francis	Taylor & Francis, 1, 5.56% Taylor & Francis 1 publication, 5.56%
Pharmaceutical Society of Japan	Pharmaceutical Society of Japan, 1, 5.56% Pharmaceutical Society of Japan 1 publication, 5.56%
Springer Nature	Springer Nature, 1, 5.56% Springer Nature 1 publication, 5.56%
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii	Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii, 1, 5.56% Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii 1 publication, 5.56%
	1 2 3 4

We do not take into account publications without a DOI.
Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.

PDF

Metrics

Cite this

GOST |

Cite this

GOST Copy

Holshouser S. et al. Epigenetic Reexpression of Hemoglobin F Using Reversible LSD1 Inhibitors: Potential Therapies for Sickle Cell Disease // ACS Omega. 2020. Vol. 5. No. 24. pp. 14750-14758.

GOST all authors (up to 50) Copy

Holshouser S., Cafiero R., Robinson M., Kirkpatrick J., Casero R. A., Hyacinth H. I., Woster P. M. Epigenetic Reexpression of Hemoglobin F Using Reversible LSD1 Inhibitors: Potential Therapies for Sickle Cell Disease // ACS Omega. 2020. Vol. 5. No. 24. pp. 14750-14758.

RIS |

Cite this

RIS Copy

TY - JOUR

DO - 10.1021/acsomega.0c01585

UR - https://doi.org/10.1021/acsomega.0c01585

TI - Epigenetic Reexpression of Hemoglobin F Using Reversible LSD1 Inhibitors: Potential Therapies for Sickle Cell Disease

T2 - ACS Omega

AU - Holshouser, Steven

AU - Cafiero, Rebecca

AU - Robinson, Mayra

AU - Kirkpatrick, Joy

AU - Casero, Robert A.

AU - Hyacinth, Hyacinth I.

AU - Woster, Patrick M.

PY - 2020

DA - 2020/06/09

PB - American Chemical Society (ACS)

SP - 14750-14758

IS - 24

VL - 5

PMID - 32596612

SN - 2470-1343

ER -

BibTex |

Cite this

BibTex (up to 50 authors) Copy

@article{2020_Holshouser,

author = {Steven Holshouser and Rebecca Cafiero and Mayra Robinson and Joy Kirkpatrick and Robert A. Casero and Hyacinth I. Hyacinth and Patrick M. Woster},

title = {Epigenetic Reexpression of Hemoglobin F Using Reversible LSD1 Inhibitors: Potential Therapies for Sickle Cell Disease},

journal = {ACS Omega},

year = {2020},

volume = {5},

publisher = {American Chemical Society (ACS)},

month = {jun},

url = {https://doi.org/10.1021/acsomega.0c01585},

number = {24},

pages = {14750--14758},

doi = {10.1021/acsomega.0c01585}

}

MLA

Cite this

MLA Copy

Holshouser, Steven, et al. “Epigenetic Reexpression of Hemoglobin F Using Reversible LSD1 Inhibitors: Potential Therapies for Sickle Cell Disease.” ACS Omega, vol. 5, no. 24, Jun. 2020, pp. 14750-14758. https://doi.org/10.1021/acsomega.0c01585.

Publisher

American Chemical Society (ACS)

Journal

ACS Omega

scimago Q1

wos Q2

SJR

0.773

CiteScore

7.1

Impact factor

4.3

ISSN

24701343 (Print, Electronic)